Prime Highlight
- Arabian Ethicals has formed a strategic partnership with Accord Healthcare to improve nationwide access to essential cancer and critical oncology treatments in the UAE.
- The collaboration strengthens efforts to meet rising patient needs and enhance healthcare service standards across hospitals, clinics, and pharmacies.
Key Facts
- Accord Healthcare offers a global oncology portfolio of 37 therapies, including treatments for breast cancer, prostate cancer, and hematological conditions.
- The partnership will introduce upcoming innovations such as biosimilars and novel therapies, supported by Accord’s R&D investments and its London-based biologics and vaccine facility, Accord Biopharma.
Background
Arabian Ethicals, a Ghobash Group enterprise, has entered a strategic partnership with UK-based Accord Healthcare to make essential cancer and critical oncology treatments more accessible across the UAE. This partnership takes a big step toward providing patients nationwide with high-quality, life-saving medicines.
Arabian Ethicals has spent 48 years building the UAE’s healthcare system and plays a key role in supplying hospitals, clinics, and pharmacies with trusted pharmaceutical and wellness brands. The new partnership allows the company to reach more patients, improve service quality and solidify its position as a leading healthcare distributor in the region.
Ebru Yavuz, General Manager of Arabian Ethicals, said the collaboration reflects the company’s commitment to raising service standards and supporting healthcare providers. She noted that partnering with Accord will enhance access to crucial oncology treatments at a time when patient needs are increasing.
Accord Healthcare brings a robust global oncology portfolio, including 37 therapies that cover common cancers such as breast and prostate tumours, as well as hematological conditions. The company will use its strong manufacturing skills and global reach to make affordable, high-quality treatments more widely available in the UAE.
The partnership will also introduce upcoming innovations from Accord’s pipeline, including biosimilars and novel therapies. These developments are backed by Accord’s investments in research and development, including its dedicated biologics and vaccine facility, Accord Biopharma, in London.
Hany Mashaal, Commercial Director MENA at Accord Healthcare, said the collaboration will help ensure UAE patients benefit from Accord’s global expertise in generics, biosimilars, and oncology solutions.
Both organisations plan to build a long-term framework that supports healthcare providers and improves patient outcomes. The partnership strengthens their shared mission to expand treatment access and contribute to the UAE’s growing healthcare sector.
